The tweet was deleted by the author.
But we saved everything 🙂.
Spyre Therapeutics, Inc. has announced the appointment of Paul Fehlner as Chief IP Counsel, bringing more than thirty years of experience at the intersection of science and law.
Fehlner is tasked with safeguarding the company innovations and intellectual property strategy as Spyre Therapeutics, Inc. advances in its research and development efforts.
Spyre Therapeutics, Inc. was recently named a 2026 IncBestWorkplaces honoree for its collaborative workplace culture. The company is also pursuing advanced therapies for ulcerative colitis and Crohn’s disease. These developments come as Spyre expands its research and development initiatives.